

Table 1. Laboratory Evaluations at Visit Week After Initiation of HCV Treatment (Genotype 1)

Lab Evaluation	During HCV Therapy													Post HCV Therapy			
	2	4	6	8	12	16	20	24	28	32	40	44	48	4	8	12	24
CBC/Diff/PLTS	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
AST/ALT		X		X		X	X		X	X	X	X		X	X	X	X
Bilirubin Direct					X			X					X				X
PT/PTT					X			X					X				X
AFP					X			X					X				X
ANA					X			X					X				X
TSH					X			X					X				X
Uric acid					X			X					X				X
Triglycerides (fasting)					X			X					X				X
HCV (quantitative)					X			X					X				X

Table 2. Parameters for Dose Reduction

Parameter	Dose Reduction	Permanent Discontinuation of Treatment (Both pegylated interferon and ribavirin)
Hemoglobin	< 10 g/dL (Ribavirin)*	< 8.5 g/dL
White Blood Cell	< 1.5 x 10 ⁹ /L (Interferon)*	< 1.0 x 10 ⁹ /L
Neutrophil Count	< 0.75 x 10 ⁹ /L (Interferon)*	< 0.5 x 10 ⁹ /L
Platelet Count	< 80 x 10 ⁹ /L (Interferon)*	< 50 x 10 ⁹ /L
Bilirubin Indirect	> 5 mg/dL (Ribavirin)*	4.5 mg/dL (for >4 weeks)
Bilirubin Direct		> 2.5 x upper limit of normal
Creatinine		> 2.0 mg/dL
ALT / AST		> 2 x baseline AND > 19 x upper limit of normal

Table 3. Dose Reduction

MEDICATION	INITIAL DOSE	TOTAL NO. OF CAPSULES/DOSES	REDUCED DOSE	TOTAL NO. OF CAPSULES/DOSES
Pegylated Interferon				
Pegasys	180 mcg SC/wk	NA	135 mcg SC/wk	NA
Peg-Intron	1.5 mcg/kg SC/wk		0.75mcg/kg SC/wk	
Ribavirin	800 mg QD	2 capsules am/ 2 capsules pm	600 mg QD (dec. 200 at a time)	1 capsule am/ 2 capsules pm
	1000mg QD(<75kg)	3 capsules am/ 2 capsules pm	800mg QD (dec. 200 at a time)	2 capsules am/ 2 capsules pm
	1200mg QD(>75kg)	3 capsules am 3 capsules pm	1000 mg QD (dec. 200 mg at a time)	2 capsule am/ 3 capsules pm